Increasing Awareness of Soft-Tissue Sarcoma: Podcast of a Patient-HCP Discussion.

IF 3.2 Q2 ONCOLOGY

Oncology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-05-13 DOI:10.1007/s40487-025-00342-6

Gillian Faskin, Sam Hackett

{"title":"Increasing Awareness of Soft-Tissue Sarcoma: Podcast of a Patient-HCP Discussion.","authors":"Gillian Faskin, Sam Hackett","doi":"10.1007/s40487-025-00342-6","DOIUrl":null,"url":null,"abstract":"<p><p>Soft-tissue sarcoma is a rare cancer, making up less than 1% of new cancer diagnoses. They comprise tumours of the connective tissue, and as such can arise in any part of the body and can mimic other conditions. In addition, there are over 80 subtypes of sarcoma which, combined with the fact that most general practitioners may only see one case of sarcoma in their working lifetime, makes them difficult to diagnose. Sarcoma UK's national sarcoma survey (2020) showed that 23% of patients started their treatment for an incorrect diagnosis before receiving their correct sarcoma diagnosis. Given the rarity of sarcoma, it is critical that patients are seen by a specialised sarcoma service as soon as possible so that all appropriate treatment pathways can be made available. However, 13% of patients never get to see a specialist multidisciplinary team. It is clear that many challenges remain in identifying patients with sarcoma and ensuring that they receive the best care possible. In this podcast a patient with sarcoma and a specialist sarcoma nurse discuss the patient's journey from initial diagnosis through to treatment and recovery. They will also discuss the physiological, emotional and mental impact that sarcoma had, as well as the critical role of the cancer nurse specialist within the treatment plan, alongside a patient support group. Listeners to the podcast will gain a better understanding of the challenges in diagnosing soft-tissue sarcoma, the tools that are already available to assist physicians in diagnosis, and the importance of providing patients with clear information throughout the treatment journey. Podcast Audio (MP4 804666 KB).</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":"293-305"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12129877/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40487-025-00342-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/13 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Soft-tissue sarcoma is a rare cancer, making up less than 1% of new cancer diagnoses. They comprise tumours of the connective tissue, and as such can arise in any part of the body and can mimic other conditions. In addition, there are over 80 subtypes of sarcoma which, combined with the fact that most general practitioners may only see one case of sarcoma in their working lifetime, makes them difficult to diagnose. Sarcoma UK's national sarcoma survey (2020) showed that 23% of patients started their treatment for an incorrect diagnosis before receiving their correct sarcoma diagnosis. Given the rarity of sarcoma, it is critical that patients are seen by a specialised sarcoma service as soon as possible so that all appropriate treatment pathways can be made available. However, 13% of patients never get to see a specialist multidisciplinary team. It is clear that many challenges remain in identifying patients with sarcoma and ensuring that they receive the best care possible. In this podcast a patient with sarcoma and a specialist sarcoma nurse discuss the patient's journey from initial diagnosis through to treatment and recovery. They will also discuss the physiological, emotional and mental impact that sarcoma had, as well as the critical role of the cancer nurse specialist within the treatment plan, alongside a patient support group. Listeners to the podcast will gain a better understanding of the challenges in diagnosing soft-tissue sarcoma, the tools that are already available to assist physicians in diagnosis, and the importance of providing patients with clear information throughout the treatment journey. Podcast Audio (MP4 804666 KB).

查看原文本刊更多论文

提高对软组织肉瘤的认识：患者- hcp讨论播客。

软组织肉瘤是一种罕见的癌症，占新癌症诊断的不到1%。它们包括结缔组织的肿瘤，因此可以在身体的任何部位出现，并可以模仿其他情况。此外，肉瘤有80多种亚型，再加上大多数全科医生在其工作生涯中可能只见过一例肉瘤，这使得肉瘤很难诊断。Sarcoma UK的全国肉瘤调查（2020年）显示，23%的患者在得到正确的肉瘤诊断之前就开始接受错误诊断的治疗。鉴于肉瘤的罕见性，患者必须尽快接受专门的肉瘤服务，以便提供所有适当的治疗途径。然而，13%的患者从未见过专业的多学科团队。很明显，在确定肉瘤患者并确保他们得到最好的治疗方面仍然存在许多挑战。在这期播客中，一位肉瘤患者和一位肉瘤专科护士讨论了患者从最初的诊断到治疗和康复的过程。他们还将讨论肉瘤对生理、情感和精神的影响，以及癌症护理专家在治疗计划中的关键作用，以及患者支持小组。播客的听众将更好地了解软组织肉瘤诊断的挑战，帮助医生进行诊断的工具，以及在整个治疗过程中为患者提供清晰信息的重要性。播客音频（MP4 804666 KB）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology and Therapy ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

6 weeks

期刊介绍： Now indexed in PubMed Aims and Scope Oncology and Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Oncology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital features and plain language summaries Oncology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor. Copyright Oncology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0 Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of £3650/€4500/$5100. The journal will consider fee discounts for developing countries and this is decided on a case by case basis. Open Access All articles published by Oncology and Therapy are published open access Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.